An article on the results of clinical monitoring of patients with a diagnosis of cervical dysplasia was published in the International Journal of Clinical Oncology and Cancer Research 
The authors of the article were 11 gynecologists and gynecologists-oncologists from leading clinics of Ukraine. The study showed that immunotherapy of cervical dysplasia with the use of peptides has significantly better clinical efficacy compared to the control group. Taking into account the obtained results and the given clinical cases, peptide immunocorrection using Areсur can be reasonably recommended as an immunological component in the treatment of cervical dysplasia of the ASCUS and LSIL stages.

Full text